ACC to launch initiative to improve awareness, care in hypertrophic cardiomyopathy
The American College of Cardiology announced it received a grant from Bristol Myers Squibb to launch the Accelerating Innovation for Medical Excellence in Hypertrophic Cardiomyopathy initiative.
According to an association press release, the AIME HCM initiative is designed to increase awareness and understanding of hypertrophic cardiomyopathy, activate clinicians and optimize disease management to improve outcomes.
Following a comprehensive survey of cardiologists in early 2020, the ACC developed education modules to increase awareness of the diagnosis and treatment of hypertrophic cardiomyopathy.
During the 2.5-year initiative, the ACC will provide education, clinical guidance and practical tools and solutions to support clinicians in identifying and managing hypertrophic cardiomyopathy. Education will include expert videos, patient cases, interactive learning modules and podcasts, according to the release. The AIME HCM initiative will also support clinician roundtables and patient forums to ensure those managing and living with hypertrophic cardiomyopathy are heard.
“The ACC is mission-driven to transform cardiovascular care for all of our patients. There is a real need for actionable tools for physicians and patients to more effectively diagnose and manage hypertrophic cardiomyopathy,” Athena Poppas, MD, FACC, president of the ACC, director of the Lifespan Cardiovascular Institute in Providence, Rhode Island and chief of cardiology and professor of medicine at the Warren Alpert School of Medicine at Brown University, said in the release. “Through this collaboration with BMS, we are extending our guidelines to implementation and education, thereby further ensuring that patients receive the most up-to-date, high-quality care.”
In December 2020, the ACC published its Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy.
“We are committed to supporting cardiologists to ensure they have the tools they need to appropriately manage HCM patients,” Samit Hirawat, MD, chief medical officer of Bristol Myers Squibb, said in the release. “We are proud to provide a grant to ACC for clinician education and awareness which is essential to close the gaps around HCM and help improve patient outcomes.”